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The human brain contains approximately 25% of the body’s cholesterol. The brain is separated from the
circulation by the blood brain barrier. While cholesterol will not passes this barrier, oxygenated forms of
cholesterol can cross the barrier. Here by measuring the difference in the oxysterol content of blood
plasma in the jugular vein and in a forearm vein by mass spectrometry (MS) we were able to determine
the ﬂux of more than 20 cholesterol metabolites between brain and the circulation. We conﬁrm that 24S-
hydroxycholesterol is exported from brain at a rate of about 2–3 mg/24 h. Gas chromatography (GC)–MS
data shows that the cholesterol metabolites 5a-hydroxy-6-oxocholesterol (3b,5a-dihydroxycholestan-6-
one), 7b-hydroxycholesterol and 7-oxocholesterol, generally considered to be formed through reactive
oxygen species, are similarly exported from brain at rates of about 0.1, 2 and 2 mg/24 h, respectively.
Although not to statistical signiﬁcance both GC–MS and liquid chromatography (LC)–MS methods indi-
cate that (25R)26-hydroxycholesterol is imported to brain, while LC–MS indicates that 7a-hydroxy-3-
oxocholest-4-enoic acid is exported from brain.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The human brain contains about 25% of the body’s cholesterol,
and cholesterol makes up about 2% of brain [1]. The brain is iso-
lated from the circulation by the blood brain barrier (BBB) which
is impermeable to cholesterol. The consequence of this is thatessentially all brain cholesterol is synthesised from acetyl CoA in
brain itself. The half life of cholesterol in human brain is about
5 years [2]. It is metabolised in brain by the cytochrome P450
(CYP) 46A1 enzyme to 24S-hydroxycholesterol (24S-HC, cholest-
5-en-3b,24S-diol), which by virtue of the added hydroxy group to
the cholesterol side-chain can pass the BBB and be exported from
brain at a reported rate of about 4–7 mg/24 h [3–5]. It is believed
that export of 24S-HC correspond to about 2/3 of cholesterol
turn-over in brain of rodents, the origin of the remaining 1/3 has
yet to be established [1]. In contrast to 24S-HC, (25R)26-hydroxy-
cholesterol (26-HC) is reported to be imported to human brain at a
rate of about 4–5 mg/24 h [5,6]. Note, we use the systematic
nomenclature where addition of a hydroxy group to a terminal
carbon atom of the cholesterol side-chain introducing R stereo-
chemistry at C-25 results in the oxysterol named (25R)26-hydrox-
ycholesterol [7]. The commonly used, but systematically incorrect,
name for this compound is 27-hydroxycholesterol. Despite the
high rate of import of 26-HC into brain the level of 26-HC in human
brain (1–2 ng/mg) is much lower than that of 24S-HC (20 ng/mg)
[8]. Interestingly, Meaney et al. have reported that the 26-HC
metabolite 7a-hydroxy-3-oxocholest-4-enoic acid (7aH,3O-CA) is
exported from brain at a rate of about 2 mg/24 h, accounting for
much of the consumption of 26-HC in brain [9].
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chromatography (LC)–MS have been exploited widely for measure-
ment of plasma or serum oxysterols [10–15]. In this work we have
utilised both these methods measuring the levels of cholesterol
metabolites in the jugular vein and a vein within the arm allowing
us to measure the rate of ﬂux of cholesterol metabolites out from,
and into, brain.2. Methods
2.1. Patient samples
Plasma was from Policlinico Umberto I, Rome, provided with
written informed consent, institutional review board and ethical
approval, and collected according to the principles of the Declara-
tion of Helsinki. Sixteen males and two females were enrolled in
the study. Sixty percent were current smokers, and 45% were also
affected by type 2 diabetes and under oral antidiabetic medica-
tions. Patients were also taking medications which included anti-
platelets, betablockers, angiotensin converting enzyme inhibitors,
and statins. Export of cerebral oxysterols from brain was studied
by measuring the gradient of concentration between the jugular
vein (blood exiting the brain) and a forearm vein sample taken
from 18 coronary heart disease patients undergoing on-pump
myocardial revascularization surgery. Blood from the jugular vein
was drawn in the intensive care unit through a 4F catheter, which
was placed in the right jugular bulb via echoscan guide and posi-
tion conﬁrmed by neck X-ray.
Blood was collected in EDTA tubes; plasma was separated
within 2 h of collection and stored at 80 C until assay.2.2. GC–MS analysis
Oxysterols were determined by GC–MS using deuterium-
labelled internal standards as described by Dzeletovic et al. and
Iuliano et al. [14,15]. In brief, 10 lL BHT in ethanol (5 mg/mL)
and 50 lL EDTA (10 mg/mL) were added to a solution of 1 mL of
plasma and 10 lL of ethanol containing deuterium labelled inter-
nal standards. Samples were subjected to alkaline hydrolysis
(600 lL ethanolic KOH 5.9 M) for 2 h at room temperature with
stirring. At the end of incubation, the solution was neutralised with
200 lL phosphoric acid and sterols extracted in chloroform:meth-
anol (2:1, v/v). Solvent was evaporated under a stream of nitrogen,
the residue dissolved in 1 mL of toluene, and oxysterols separated
from cholesterol by solid phase extraction. Silica cartridges
(100 mg), previously equilibrated with n-hexane, were loaded with
toluene-dissolved samples. Cholesterol and non-cholesterol neu-
tral sterols were eluted with 1% propan-2-ol in hexane before elut-
ing oxysterol with 10% propan-2-ol in n-hexane. After removal of
solvent, samples were converted to trimethylsilyl ethers by treat-
ment with 130 lL Sylon HTP (hexamethyldisilylazane:trimethyl-
chlorosilane:pyridine, 3:1:9) (Supelco, Bellafonte, PA) at 60 C for
30 min. After incubation, the solution was evaporated under a
stream of nitrogen, and the residue dissolved in n-hexane and
transferred to an autosampler vial. Analyses were performed on
an Agilent 6890N GC equipped with a 7683 series automatic liquid
sampler, and interfaced with an Agilent 5973 Mass Spectrometer
(Agilent Technologies; Palo Alto, CA). Separation was carried out
on a 30 m capillary column (HP-5MS 30  0.25 mm ID, 0.25 lm
thickness). Quantiﬁcation of oxysterols was made by the isotope
dilution method.
3b,5a-Dihydroxycholestan-6-one (3b,5a-diHC-6O), 3b,5a-[2H6]
dihydroxycholestan-6-one ([2H6]-3b,5a-diHC-6O), cholestane-
3b,5a,6b-triol (C-triol) and [2H6]cholestane-3b,5a,6b-triol ([2H6]-
C-triol) were synthesised as previously described [16]. 4a- and4b-hydroxyholesterols (4a-HC, 4b-HC), synthesised as described
in [17], were kindly donated by G. Lizard, Université de Bourgogne.
All other deuterated and non-deuterated oxysterols were from
Avanti Polar Lipids (Alabaster, AL).
2.3. LC–MS analysis
Oxysterols were analysed as their Girard P (GP) derivatives
using deuterium labelled internal standards as described in Grif-
ﬁths et al. and Crick et al. [18,19]. In brief, 100 lL of plasma was
added to 1.05 mL of ethanol containing deuterated internal
standards 24S-[2H7]hydroxycholesterol, 22R-[2H7]hydroxycholes-
terol, 22R-[2H7]hydroxycholest-4-en-3-one, 7a-[2H7]hydroxycho-
lesterol, 7a,25-[2H6]dihydroxycholesterol and [2H7]cholesterol
(Avanti). The solution was diluted to 70% ethanol and centrifuged.
The supernatant (1.5 mL 70% ethanol) was loaded on a Sep-Pak tC18
200 mg cartridge (Waters, Elstree, UK) and the ﬂow-through and a
5.5 mL wash with 70% ethanol combined. This fraction, the oxy-
sterol fraction, was dried under reduced pressure, re-constituted
in 100 lL of propan-2-ol and treated with KH2PO4 buffer (1 mL
50 mM, pH 7) containing 3 lL of cholesterol oxidase (2 mg/mL in
H2O, 44 units/mg protein) for 1 h at 37 C. Methanol (2 mL), glacial
acetic acid (150 lL) and GP reagent (150 mg, 0.8 mmole) were
added and the mixture incubated at room temperature over night.
To remove excess derivatisation agent the reaction mixture was
applied to a 60 mg OASIS HLB cartridge (Waters). A re-cycling pro-
tocol was adopted where the eluate is diluted with an equal vol-
ume of water and re-cycled on the column until the eluate is
17.5% methanol (19 mL). After a wash with 10% methanol (6 mL)
GP-derivatised oxysterols were eluted in methanol (2 mL).
In contrast to sample preparation for GC–MS analysis, hydroly-
sis was not performed for LC–MS, hence non-esteriﬁed oxysterols
were measured by LC–MS while total oxysterols by GC–MS.
2.4. Statistics
Paired sample t tests were performed. P < 0.05 was considered
statistically signiﬁcant. ⁄P < 0.05; ⁄⁄P < 0.01.
3. Results
3.1. GC–MS
Using GC–MS we measured the levels of 12 oxysterols in the
jugular vein and in a vein in the forearm. Of these, we found
statistical differences in the levels of 7b-hydroxycholesterol (7b-
HC, P < 0.05), 7-oxocholesterol (7-OC, P < 0.05), 3b,5a-diHC-6O
(P < 0.01) and 24S-HC (P < 0.01) corresponding to a ﬂux of about
2, 2, 0.1 and 3 mg/24 h out from brain, assuming a ﬂow of plasma
of 450 mL/min through brain [6] (Fig. 1 and Supplementary data
Table S1).
3.2. LC–MS
Using LC–MS we similarly measured the levels of 20 cholesterol
metabolites and also 25-hydroxyvitamin D3 (25-D3). An important
methodological difference between the LC–MS and the GC–MS
analysis was that only non-esteriﬁed metabolites were measured
by LC–MS. We found a statistical difference in the concentration
of 24S-HC (P < 0.01) between the two veins, corresponding to a ﬂux
from brain of about 2 mg/24 h. In an earlier report we noted that
7a,25-dihydroxycholest-4-en-3-one (7a,25-diHCO, P < 0.01) and
7a,(25R)26-dihydroxycholest-4-en-3-one (7a,26-diHCO, P < 0.01)
were similarly exported from brain at a rate of about 0.5 and
1 mg/24 h, respectively [19] (Fig. 2 and Supplementary data
Table S2).
Fig. 2. Flux of sterols out from (positive value) and into (negative value) brain.
Plasma concentrations of sterols in the jugular vein and a forearm vein taken from
coronary heart disease patients (n = 18) undergoing on-pump myocardial revascu-
larization surgery were measured by LC–MS. The ﬂux of sterol out from and into
brain was calculated based on jugular vein and forearm vein differences assuming a
ﬂow of plasma to the brain of 450 mL/min. Individual data points are represented
by ﬁlled circles. Mean values are indicated by a solid bar. Paired sample t tests were
performed. ⁄P < 0.05; ⁄⁄P < 0.01. Data for 7a,25-diHCO and 7a,26-diHCO has been
reported previously [19]. See Supporting information Table S2 for a full list of all
compound abbreviations.
Fig. 1. Flux of sterols out from (positive value) and into (negative value) brain.
Plasma concentrations of sterols in the jugular vein and a forearm vein taken from
coronary heart disease patients (n = 18) undergoing on-pump myocardial revascu-
larization surgery were measured by GC–MS. The ﬂux of sterol out from and into
brain was calculated based on jugular vein and forearm vein differences assuming a
ﬂow of plasma to the brain of 450 mL/min. Paired sample t tests were performed.
⁄P < 0.05; ⁄⁄P < 0.01.
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As mentioned in Section 1, there have been three previous stud-
ies investigating the ﬂux of oxysterols from brain. Lütjohann et al.
measured differences in oxysterol levels in plasma from the jugular
vein and a brachial artery from 8 volunteers and found the ﬂux of
24-HC out from brain into the circulation to be about 4 mg/24 h
[3]. Björkhem et al. and Heverin et al. similarly measured the ﬂux
of oxysterols from brain from an additional 12 healthy subjects and
also found 24-HC to be exported at a rate of about 6 mg/24 h, while
26-HC was imported to brain at a rate of about 4–5 mg/24 h [4,6].
In a further study, Meaney et al. measured the levels of choleste-
noic acids in the jugular vein and brachial artery from 9 healthy
subjects and found that 7aH,3O-CA is exported at a rate of about
2 mg/24 h from brain.
In the current study we have measured the differences in con-
centration of 18 oxysterols, 5 cholestenoic and 3 cholenoic acids
between the jugular vein and a forearm vein taken from 18 coro-
nary heart disease patients undergoing on-pump myocardial
revascularization surgery. We ﬁnd that 24S-HC is exported from
brain at a rate of 2–3 mg/24 h.
Three other oxysterols, 7b-HC, 7O-C and 3b,5a-diHC-6O, were
exported from brain at rates of about 2–0.1 mg/24 h. These differ-
ences were only observed when total oxysterols were measured.
These three compounds are considered to be formed from choles-
terol through reactive oxygen species (ROS) and might indicate
oxidative stress activity in the brain. In particular, 3b,5a-diHC-6O
can be formed chemically by ozone or via ozone-like mechanisms
[20–22] in a pathway that might occur in the brain [23]. However,
recent evidence supports the occurrence of an enzymatic-mediated
mechanism of 3b,5a-diHC-6O formation using C-triol as a sub-
strate (unpublished data). Since C-triol is formed by epoxide
hydrolase that uses 5,6-epoxides as substrates [24], 3b,5a-diHC-
6Omay provide a speciﬁc form of transport out of the brain for oxi-
dative stress-derived cholesterol epoxides.
Although not showing statistical signiﬁcance both GC–MS anal-
ysis for total oxysterols and LC–MS analysis for non-esteriﬁed
metabolites indicate import of 26-HC to brain. LC–MS analysis
for 7aH,3O-CA indicate that this metabolite is exported from brain
(Fig. 2). This result was observed for 13 of the 18 patients studied.
We recently reported that two other cholesterol metabolites
7a,25-diHCO (16/18 patients) and 7a,26-diHCO (16/18 patients)
were exported from brain at rates of about 0.5 and 1 mg/24 h(Fig. 2) [19]. Therefore our data and that of others indicate that
there are in fact multiple routes for export of cholesterol metabo-
lites from brain (Fig. 3). The major exported oxysterol is 24S-HC,
this is formed from cholesterol in a CYP46A1 catalysed reaction.
CYP46A1 is known to be expressed in brain [25]. Other exported
oxysterols include 7b-HC, 7O-C and 3b,5a-diHC-6O. These oxyster-
ols are likely to be formed from cholesterol by ROS [21]. On the
other hand, 26-HC is imported from the circulation into brain [6].
In brain 26-HC can be metabolised via the ‘‘acidic pathway’’ of bile
acid biosynthesis [26]. One branch of this pathway is via
7a,(25R)26-dihydroxycholesterol (7a,26-diHC) and 7a,26-diHCO
leading to 7aH,3O-CA. The latter two compounds are found to be
exported from brain [9,19]. 7a,26-diHC is formed from 26-HC via
the enzyme CYP7B1, known to be expressed in brain [27], and then
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192 L. Iuliano et al. / Steroids 99 (2015) 189–193converted to 7a,26-diHCO by the enzyme HSD3B7 and ultimately
to 7aH,3O-CA via CYP27A1 [26]. CYP7B1 and HSD3B7 similarly
metabolise 25-HC through to 7a,25-dihydroxycholesterol (7a,25-
diHC) and ultimately to the export product 7a,25-diHCO, respec-
tively. The second branch of the acidic pathway from 26-HC
involves further oxidation by CYP27A1 to generate 3b-hydroxycho-
lest-5-en-(25R)26-oic acid (3b-HCA) followed by 7a-hydroxylation
via CYP7B1 to give 3b,7a-dihydroxycholest-5-enoic acid (3b,
7a-diHCA). Neither of these latter metabolites are exported from
brain.
A limitation of the current study is that the patients took several
mediations that, potentially, could have affected the results.
Having found, however, both enzymatic and non-enzymatic oxys-
terols are exported from the brain, a potential drug-derived bias
seems unlikely, although one cannot be ruled out. In addition,
results on 24S-HC are conﬁrmatory of previous studies carried
out in healthy volunteers [3,4,6]. On the other hand, the data of
the present study were obtained in patients with coronary heart
disease (CHD) and might not apply to other clinical settings or to
healthy individuals. Notably, the efﬂux of oxysterols pertinent to
the oxidative stress pathway may be associated with brain injury
dependent on alterations of the cerebral vasculature likely to be
present in patients with CHD. If this hypothesis holds true these
oxysterols would provide a link in support of the theory of vascu-
lar-driven neurodegeneration [28].Acknowledgements
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